A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521737-91-00

Acronym

MK-1084-014

Enrollment

Registered

2025-11-12

Start date

2025-11-25

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm malignant with KRAS G12C mutation

Brief summary

Objective Response Rate (ORR), Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE

Detailed description

Overall Survival (OS), Duration of Response (DOR), Progression-free Survival (PFS)

Interventions

DRUGMK-1084

DRUGCETUXIMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response Rate (ORR), Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE	—

Secondary

Measure	Time frame
Overall Survival (OS), Duration of Response (DOR), Progression-free Survival (PFS)	—

Countries

Denmark, France, Germany, Greece, Italy, Norway, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026